Evidence map›Paper›PMID 35689566›Full record

ArticleJournal of clinical laboratory analysis2022

Arctigenin inhibits apoptosis, extracellular matrix degradation, and inflammation in human nucleus pulposus cells by up-regulating miR-483-3p.

Zhe Ji, Rui Guo, Zhigang Ma, Hongwei Li

Abstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Immunopharmacological potential ofFrontiers in pharmacology · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhe JiOrthopedic Center Spine Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Rui GuoOrthopedic Center Spine Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Zhigang MaOrthopedic Center Spine Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Hongwei LiOrthopedic Center Spine Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.ORCID https://orcid.org/0000-0001-7082-4329

Funding

Natural Science Foundation of Xinjiang Uygur Autonomous Region 2022D01F22
6 · The paper itself

Abstract

backgroundArctigenin (ATG) is the active ingredient of the Chinese herbal medicine Arctium lappa, with anti-inflammatory and antioxidant effects. Excessive inflammation and cell apoptosis are important causes of intervertebral disc degeneration (IDD). Hence, this study probed into the possible role of ATG in IDD.

methodsInterleukin (IL)-1β (10 ng/ml) was adopted to induce human nucleus pulposus cells (HNPCs) as a cell model for IDD. The effects of different concentrations of ATG (0, 2, 5, 10, 20, 50 μmol/L) on the viability of HNPCs and effects of ATG (10, 50 μmol/L) on the viability of IL-1β-induced HNPCs were detected by cell counting kit-8 (CCK-8). After IL-1β-induced HNPCs were transfected with miR-483-3p inhibitor and/or treated with ATG, cell viability and apoptosis were determined by CCK-8 and flow cytometry; the expressions of miR-483-3p, extracellular matrix (ECM)-related genes, and inflammation-related genes were measured by quantitative real time polymerase chain reaction (qRT-PCR), and expressions of ECM/apoptosis/NF-κB pathway-related proteins were quantified by Western blot.

resultsATG had no significant effect on the viability of HNPCs but could promote the viability of IL-1β-induced HNPCs. ATG inhibited apoptosis, ECM degradation, inflammation, and activation of NF-κB pathway in HNPCs induced by IL-1β, but promoted the expression of miR-483-3p. MiR-483-3p inhibitor reversed the above-mentioned regulatory effects of ATG.

conclusionArctigenin suppresses apoptosis, ECM degradation, inflammation, and NF-κB pathway activation in HNPCs by up-regulating miR-483-3p.

Indexed as

FuransIntervertebral Disc DegenerationLignansMicroRNAsNucleus PulposusApoptosisCells, CulturedExtracellular MatrixExtracellular Matrix ProteinsHumansInflammationNF-kappa BarctigeninExtracellular Matrix ProteinsFuransLignansMicroRNAsMIRN483 microRNA, humanNF-kappa Barctigeninhuman nucleus pulposus cellsintervertebral disc mutationmiR-483-3p

Identifiers

PMID35689566
PMCPMC9280009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.